APUS vs DASH · $2.4M cap vs P/E 76, rev $13.72B
Apimeds Pharmaceuticals US, Inc. (APUS) versus DoorDash, Inc. Class A Common Stock (DASH) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
APUS does not have a complete income-statement cache yet.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
APUS currently screens at market cap $2.4M. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Not investment advice. Open the APUS and DASH stock pages for the full models.
Not investment advice.